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Fern Hamomba, Portipher Pilingana, Andisen Zulu, Pascalina Chanda-Kapata, Godfrey Biemba, Donald M Thea, William B MacLeod, 
Jonathon L Simon, Davidson H Hamer
Summary
Background Chlorhexidine umbilical cord washes reduce neonatal mortality in south Asian populations with high 
neonatal mortality rates and predominantly home-based deliveries. No data exist for sub-Saharan African populations 
with lower neonatal mortality rates or mostly facility-based deliveries. We compared the effect of chlorhexidine with 
dry cord care on neonatal mortality rates in Zambia.
Methods We undertook a cluster-randomised controlled trial in Southern Province, Zambia, with 90 health facility-
based clusters. We enrolled women who were in their second or third trimester of pregnancy, aged at least 15 years, 
and who would remain in the catchment area for follow-up of 28 days post-partum. Newborn babies received clean 
dry cord care (control) or topical application of 10 mL of a 4% chlorhexidine solution once per day until 3 days after 
cord drop (intervention), according to cluster assignment. We used stratified, restricted randomisation to divide 
clusters into urban or two rural groups (located <40 km or ≥40 km to referral facility), and randomly assigned clusters 
(1:1) to use intervention (n=45) or control treatment (n=45). Sites, participants, and field monitors were aware of their 
study assignment. The primary outcomes were all-cause neonatal mortality within 28 days post-partum and all-cause 
neonatal mortality within 28 days post-partum among babies who survived the first 24 h of life. Analysis was by 
intention to treat. Neonatal mortality rate was compared with generalised estimating equations. This study is 
registered at ClinicalTrials.gov (NCT01241318).
Findings From Feb 15, 2011, to Jan 30, 2013, we screened 42 356 pregnant women and enrolled 39 679 women (mean 
436·2 per cluster [SD 65·3]), who had 37 856 livebirths and 723 stillbirths; 63·8% of deliveries were facility-based. Of 
livebirths, 18 450 (99·7%) newborn babies in the chlorhexidine group and 19 308 (99·8%) newborn babies in the dry cord 
care group were followed up to day 28 or death. 16 660 (90·0%) infants in the chlorhexidine group had chlorhexidine 
applied within 24 h of birth. We found no significant difference in neonatal mortality rate between the chlorhexidine 
group (15·2 deaths per 1000 livebirths) and the dry cord care group (13·6 deaths per 1000 livebirths; risk ratio [RR] 1·12, 
95% CI 0·88–1·44). Eliminating day 0 deaths yielded similar findings (RR 1·12, 95% CI 0·86–1·47).
Interpretation Despite substantial reductions previously reported in south Asia, chlorhexidine cord applications did not 
significantly reduce neonatal mortality rates in Zambia. Chlorhexidine cord applications do not seem to provide clear 
benefits for newborn babies in settings with predominantly facility-based deliveries and lower (<30 deaths per 
1000 livebirths) neonatal mortality rates.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license
Introduction
Substantial progress has been made towards accomplish-
ment of the 4th Millennium Development Goal (MDG) to 
reduce worldwide under-5 child mortality, but many 
countries did not reach the target of a 75% reduction 
between 1990 and 2015.1 Most of the reduction in under-5 
mortality is due to interventions that affect the post-neonatal 
period; globally, 2·9 million newborn babies die each year.2 
Neonatal sepsis and prematurity have emerged as principal 
challenges to further reductions in neonatal mortality.3
Chlorhexidine cord washes have been evaluated as a 
strategy to reduce umbilical cord infections, sepsis, and 
neonatal mortality.4 Although three previous studies5–7 
found that topical chlorhexidine umbilical cord washes 
reduced neonatal mortality, the efficacy of chlorhexidine 
has not been assessed in an African population, where 
neonatal mortality rates are lower, HIV prevalence is 
higher, and delivery setting and cultural practices 
regarding cord care substantially differ from those in 
south Asia.8
Dry cord care has been the long-standing recom-
mendation of umbilical stump care for most newborn 
babies.9 Updated WHO guidelines10 recommend appli-
cation of chlorhexidine to the umbilical stump 
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immediately after birth for home births and in 
environments with high neonatal mortality rates 
(>30 deaths per 1000 livebirths). Some donor and advocacy 
groups are proposing more extensive use of chlorhexidine 
and rapid programmatic scale-up globally, but 
generalisable evidence supporting the efficacy of this 
approach outside south Asia is scarce, with no evidence 
from Africa.11 In view of the need to assess efficacy in an 
African population, we aimed to compare daily cord 
cleansing with 4% chlorhexidine with standard practice of 
dry cord care in Zambia’s Southern Province. A similar 
trial was done in Pemba Island, Tanzania.12
Methods
Study design
We did a community-based, cluster-randomised con-
trolled trial (the Zambia Chlorhexidine Application Trial 
[ZamCAT]) in Zambian Government or mission primary 
health-care centres in the Southern Province of Zambia 
(appendix). In 2007, this province had a neonatal 
mortality rate of 37 deaths per 1000 livebirths and 
maternal HIV prevalence of 14·5%.13 The design and 
methods of ZamCAT have been reported elsewhere.14 
The unit of randomisation (clusters) was the study sites 
(Zambian Government or mission primary health-care 
centres and their catchment areas). Eligible health-care 
centres provided routine antenatal services and at least 
160 annual births in their catchment area.
Participants
Study field monitors screened women attending 
antenatal care visits at eligible health centres and during 
community outreach activities for study enrolment. 
Eligible women were in their second or third trimester, 
aged 15 years or older, planning to stay in the catchment 
area until 28 days post-partum, and willing to provide 
informed consent and complete cord care as per cluster 
assignment. At enrolment, data were collected from 
women about previous and current pregnancies, 
previous obstetric complications, expected date of 
delivery, and their demographics. Participants were 
encouraged to deliver at their nearest health facility and 
were given standard newborn care messages—which 
included information about delivery location, 
breastfeeding, cord care, and danger signs of ill health in 
their newborn baby—as per national guidelines.15,16
At enrolment, study participants provided local contact 
information and study personnel with assistance from 
the study participant drew maps from the clinic to their 
home to allow field monitors to know where to go for the 
home visits. Before study initiation, investigators worked 
with local tribal and political leadership to develop 
Research in context panel 
Evidence before this study
We searched PubMed and the Cochrane Library databases with no 
date or language restrictions, using the following search terms: 
“chlorhexidine”, “umbilical cord”, and “omphalitis”. We found 
17 articles from our search. At the time of ZamCAT initiation 
(2011), only one trial (in Nepal) was published that showed 
reduced neonatal mortality rates (NMRs). Subsequently, two 
other community-based trials of chlorhexidine-cord cleansing 
were completed in Pakistan and Bangladesh. All three studies 
found decreased neonatal mortality associated with 
chlorhexidine cord applications and a meta-analysis reported a 
23% reduction in NMR (relative risk [RR] 0·77, 95% CI 0·63–0·94). 
These three studies, comparing chlorhexidine to dry cord care, 
were undertaken in densely populated rural areas of south Asia 
with high NMRs (≥30 deaths per 1000 livebirths) and 
predominantly home deliveries. Limitations of the three studies 
include mixed findings in Bangladesh when examining one 
application, which significantly reduced NMR compared with 
once a day for 7 days application; factorial design in Pakistan 
where, when handwashing is removed, there was insufficient 
power to show that chlorhexidine significantly reduced NMR; and 
in Nepal, where only infants enrolled within 24 h of birth had a 
significant reduction in NMR. 
Added value of this study
The rationale and design of ZamCAT and the Pemba Island 
studies advance the work of the previous trials in new settings 
in sub-Saharan Africa. The studies’ sample sizes and design 
were guided by published reviews on the potential effect of 
chlorhexidine interventions on neonatal health outcomes and 
were developed in conjunction with each other. Provisional 
WHO guidelines released in September, 2012, when both 
studies were underway, recommended dry cord care with 
chlorhexidine application only in settings of high NMR 
(≥30 deaths per 1000 livebirths) and home delivery. 
The ZamCAT findings challenge the assumption that, if 
chlorhexidine works in south Asia, it must work in 
sub-Saharan Africa. In the Southern Province of Zambia, with a 
relatively high rate of facility-based deliveries (63%) and lower 
NMR (14·4 deaths per 1000 livebirths), chlorhexidine did not 
reduce neonatal mortality compared with dry cord care. When 
our results are pooled with those from the Pemba Island study, 
the combined analysis shows no evidence of a mortality benefit 
for chlorhexidine cord washes compared with dry cord care 
(NMR RRpooled 1·02, 95% CI 0·86–1·20, and RRmeta 0·99, 95% CI 
0·80–1·23). 
Implications of all the available evidence
Current WHO chlorhexidine policy and guidelines might be 
appropriate in settings with high NMR and predominantly 
home deliveries. However, our results suggest that the global 
rollout of chlorhexidine is inappropriate, especially in low NMR 
settings in sub-Saharan Africa. 
See Online for appendix
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community-specific systems to notify field monitors 
about ZamCAT participant births within 24 h.14 Contact 
methods included via a personal or facility-based mobile 
phone or sending of relatives or health providers to notify 
study personnel.
The Boston University Medical Campus Institutional 
Review Board and University of Zambia Research Ethics 
Committee provided ethical approval, and the Zambian 
Ministry of Health approved the study to be undertaken in 
Zambia. All women provided written informed consent, 
which was obtained in languages of English or Tonga.
Randomisation and masking
We used stratified, restricted randomisation17 to divide 
clusters into three groups: urban, rural but located within 
40 km of the nearest referral facility, and rural and 
located 40 km or more from the referral facility. In each 
group, clusters were randomly assigned (1:1) to either 
chlorhexidine treatment (intervention) or dry cord care 
(standard practice), with restriction to achieve balance 
among five factors: health-centre catchment population, 
total births, distance to referral facility, total facility staff, 
and number of associated community-based traditional 
birth attendants. Sites and participants were aware of 
their study assignment, as were field monitors.
Procedures
Field monitors made five home visits—one antenatal and 
four postnatal (day 1, 4, 10, and 28 post-partum). The 
antenatal visit was completed within 2 weeks of 
enrolment, during which the field monitor confirmed the 
home location for follow-up, provided a standard clean 
delivery kit (which included soap, sterile razor blade, 
sterile gloves, two cord clamps, candle and matches, and 
a plastic mat) to all study participants irrespective of study 
group, reviewed study procedures with the mother, and 
screened for pregnancy danger signs.
In the chlorhexidine group, field monitors provided 
pregnant women with chlorhexidine and cotton swabs at 
the antenatal home visit, and instructed them on how 
to apply chlorhexidine to the umbilical stump. Liquid 
4% chlorhexidine formulation was supplied in single-
application 10 mL eyedropper bottles (Galentic Inc, 
Mumbai, India). Each mother in the chlorhexidine group 
received instructions and sufficient quantities for once a 
day application until 3 days after the umbilical stump had 
separated fully. The birth attendant, mother, or a relative 
applied the first dose; the mother or her family completed 
subsequent applications. Participants in the dry cord care 
group were instructed by field monitors to keep the cord 
clean, dry, and free of topical substances, in accordance 
with the Zambian Ministry of Health policy.15
At the postnatal visits, field monitors assessed and 
documented the mother’s and newborn baby’s health 
status and adherence to cluster-specific cord care. 
Mothers were asked whether any substances had been 
applied to the cord, including chlorhexidine and 
90 clusters randomly assigned
18 301 neonates alive at day 4 follow-up 
17 876 day 4 follow-up visits
18 244 neonates alive at day 10 follow-up 
17 957 day 10 follow-up visits
 18 168 neonates alive at day 28 follow-up 
 18 096 day 28 follow-up visits
 19 045 neonates alive at day 28 follow-up 
 18 968 day 28 follow-up visits
21 280 pregnant women screened 21 044 pregnant women screened
 19 165  neonates alive at day 4 follow-up 
 18 816  day 4 follow-up visits
 19 127  neonates alive at day 10 follow-up 
 18 918  day 10 follow-up visits
 38 neonates excluded
 33 neonatal deaths
 4 lost to follow-up
 1 withdrew
82 neonates excluded
 60 neonatal deaths
 21 lost to follow-up
 1 withdrew
57 neonates excluded
 45 neonatal deaths
 10 lost to follow-up
 2 withdrew
76 neonates excluded
 46 neonatal deaths
 26 lost to follow-up
 4 withdrew
18 450 neonates included in analyses 19 308 neonates included in analyses
45 clusters assigned to chlorhexidine group 45 clusters assigned to dry cord care group
18 639 women had 18 858 deliveries
 348 stillbirths
 18 510 livebirths
19 492 women had 19 721 deliveries
 375 stillbirths
 19 346 livebirths
80 neonates excluded
 77 neonatal deaths
 3 lost to follow-up
 0 withdrew
86 neonates excluded
 82 neonatal deaths
 4 lost to follow-up
 0 withdrew
18 424 neonates alive at day 1 follow-up 
 17 921  day 1 follow-up visits
19 266 neonates alive at day 1 follow-up 
 18 937 day 1 follow-up visits
101 neonates excluded
 93 neonatal deaths
 7 lost to follow-up
 1 withdrew
123 neonates excluded
 109 neonatal deaths
 8 lost to follow-up
 6 withdrew
19 629  women enrolled 20 050 women enrolled
558 excluded
 15 false preganancies
 38 miscarriages or abortions 
 46 withdrawn before delivery
 455 lost to follow-up
 4 maternal deaths before delivery
990 excluded
 27 false preganancies
 46 miscarriages or abortions 
 175 withdrawn before delivery
 740 lost to follow-up
 2 maternal deaths before delivery
630  excluded
900 declined to participate
 121 other
617 excluded
325 declined to participate
 52 other
Figure 1: Trial profile
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non-study applications. Field monitors directly examined 
the umbilical cord until detachment and thereafter the 
umbilical stump, and collected empty chlorhexidine 
bottles as confirmation of use. These assessments were 
done at each of the four visits. Any mother or newborn 
baby with danger signs or symptoms was referred to the 
health-care centre. HIV status was recorded from the 
woman’s antenatal clinic card; infants exposed to HIV 
were referred to the health centre if they had not received 
antiretroviral prophylaxis at delivery.
Field monitors collected data using forms designed in 
the TeleForms system (HP, Cambridge, UK). Supervisors 
reviewed forms for completeness and the forms were 
then scanned, entered, and exported into a Microsoft 
Access database (accessed by KEAS and AZ, who knew of 
participant group assignments). If forms were 
incomplete, field supervisors requested field monitors 
Chlorhexidine 
(n=19 629)
Dry cord care 
(n=20 050)
Age (n=19 455) (n=19 896) 
<20 years 4671 (24·0%) 4580 (23·0%)
20–35 years 12 772 (65·6%) 13 122 (66·0%)
>35 years 2012 (10·3%) 2194 (11·0%)
Median household size (IQR) 6 (4–8) 6 (4–8)
Woman’s highest level of 
education
(n=19 460)  (n=19 904) 
No education 1936 (9·9%) 1958 (9·8%)
Lower primary (grade 1–4) 2293 (11·8%) 2563 (12·9%)
Upper primary (grade 5–7) 7731 (39·7%) 7874 (39·6%)
Junior secondary (grade 8–9) 5422 (27·9%) 5499 (27·6%)
Upper secondary (grade 10–12) 1895 (9·7%) 1840 (9·2%)
>Upper secondary 180 (0·9%) 160 (0·8%)
Do not know 3 (0·02%) 10 (0·1%)
Ethnic origin or tribe (n=19 461) (n=19 912) 
Tonga 17 003 (87·4%) 17 650 (88·6%)
Ila 105 (0·5%) 121 (0·6%)
Lozi 786 (4·0%) 795 (4·0%)
Nyanja 525 (2·7%) 432 (2·2%)
Bemba 413 (2·1%) 433 (2·2%)
Other 629 (3·2%) 481 (2·4% )
Marital status (n=19 463) (n=19 910) 
Single 3021 (15·5%) 3133 (15·7%)
Married 16 107 (82·8%) 16 499 (82·9%)
Separated, divorced, or 
widowed
224 (1·2%) 187 (0·9%)
Cohabiting 109 (0·6%) 89 (0·4%)
Missing 2 (0·01%) 2 (0·01%)
Maternal literacy ability (n=19 441) (n=19 903) 
Not at all 5037 (25·9%) 5491 (27·6%)
A bit 8835 (45·4%) 9516 (47·8%)
Very well 5492 (28·2%) 4835 (24·3%)
No response 77 (0·4%) 61 (0·3%)
Household water source (n=19 439) (n=19 875) 
Household tap 1861 (9·6%) 1715 (8·6%)
Community tap 1919 (9·9%) 1761 (8·9%)
Other water source on own 
property
2295 (11·8%) 2403 (12·1%)
Community well or river 13 241 (68·1%) 13 768 (69·3%)
No answer 56 (0·3%) 62 (0·3%)
Other 67 (0·3%) 166 (0·8%)
Housing roof type (n=19 394) (n=19 853) 
Iron sheets or asbestos 8854 (45·7%) 8241 (41·5%)
Thatched grass 10 462 (53·9%) 11 531 (58·1%)
Do not know 36 (0·2%) 37 (0·2%)
Other 42 (0·2%) 44 (0·2%)
Housing wall materials (n=19 446) (n=19 904) 
Cement bricks without plaster 763 (3·9%) 767 (3·9%)
Cement bricks with plaster 2017 (10·4%) 1971 (9·9%)
Other bricks without plaster 12 780 (65·7%) 13 021 (65·4%)
Other bricks with plaster 2608 (13·4%) 2998 (15·1%)
Mud and poles 1196 (6·2%) 1063 (5·3%)
(Table 1 continues in next column)
Chlorhexidine 
(n=19 629)
Dry cord care 
(n=20 050)
(Continued from previous column)
Do not know 1 (0·005%) 3 (0·02%)
Other 81 (0·4%) 81 (0·4%)
Ownership of a TV or radio (n=19 408) (n=19 870) 
No 6909 (35·6%) 7433 (37·4%)
Radio 8390 (43·2%) 8614 (43·4%)
Television 613 (3·2%) 511 (2·6%)
Both 3496 (18·0%) 3312 (16·7%)
Household light source (n=19 448) (n=19 891) 
Electricity 1661 (8·5%) 1378 (6·9%)
Lantern (kerosene lamp) 1923 (9·9%) 2219 (11·2%)
Candle 3335 (17·1%) 3308 (16·6%)
Battery 11 506 (59·2%) 10 943 (55·0%)
Other 1023 (5·3%) 2043 (10·3%)
Time walking from home to 
health facility
(n=19 412) (n=19 854) 
<1 h 6404 (33·0%) 6784 (34·2%)
1 h to <2 h 6854 (35·3%) 7239 (36·5%)
2 h to <3 h 4179 (21·5%) 4207 (21·2%)
3 h to <4 h 1425 (7·3%) 1093 (5·5%)
4 h to <5 h 284 (1·5%) 329 (1·7%)
≥5 h 212 (1·1%) 81 (0·4%)
Unknown 54 (0·3%) 121 (0·6%)
Parity 2·4 (2·3) 2·5 (2·4)
Gravida 3·5 (2·3) 3·6 (2·4)
Had a previous child die in 
neonatal period
1536/18 366 
(8·4%)
1707/19 188 
(8·9%) 
Gestational age at enrolment 
based on LMP (weeks)
28·0 (7·2) 28·4 (7·2)
Bed net previous night* 11 092/19 402 
(57·2%)
11 783/19 858 
(59·3%)
Data are n (%), n/N (%), or mean (SD). LMP=last menstrual period. *Slept under a 
mosquito bed night before study enrolment.
Table 1: Demographic, household, and pregnancy characteristics of 
women enrolled 
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gather the data needed, but if they could not the data 
were deemed missing. A data safety monitoring board 
completed two interim analyses at one-third and two-
thirds accrual.17
Outcomes 
The primary outcomes were all-cause neonatal mortality 
within 28 days post-partum and all-cause neonatal 
mortality within 28 days post-partum among babies who 
survived the first 24 h of life. Deaths were documented by 
interview with the mother; stillbirths were defined as an 
infant who did not breathe, cry, or move at the time of 
delivery. Information was recorded on the time of birth 
and death, and surrounding circumstances. Secondary 
outcomes, reported here, were incidence of omphalitis 
(any level of severity; as defined by umbilical stump 
erythema or purulent discharge), on the basis of field 
monitors’ assessment at each study visit. Additional 
secondary outcomes included proportion of women who 
deliver at a site other than their intended delivery location 
and factors affecting where pregnant women deliver 
(which will be reported elsewhere), and characterisation 
of health service network available to pregnant and post-
partum women and their children, which has been 
reported elsewhere.18 Adverse events were defined 
as chlorhexidine-related events including accidental 
ingestion, accidental ocular exposure, contact dermatitis, 
or skin irritation around the umbilical stump, and 
anaphylaxis. A technical advisory group convened twice 
during the study to review study progress.
Statistical analysis
Even though a mortality reduction of 34% was reported 
in Nepal,5 we used a more conservative 25% reduction 
for the sample size calculations. Assuming that the 
national neonatal mortality rate of 37 deaths per 
1000 births included stillbirths or early neonatal deaths 
(Zambia Demographic Health Survey [DHS] 2007), we 
expected the dry cord care neonatal mortality rate to be 
29 deaths per 1000 livebirths. With 90% power to detect a 
25% reduction of the neonatal mortality rate from 
29 deaths per 1000 livebirths in the dry cord care group 
(k=0·20 and α=0·05), 90 clusters with 320 births per 
cluster were needed (total sample size 28 800 newborn 
babies or 14 400 babies per group). To account for any 
potential loss to follow-up, we increased the sample size 
by 10%. Just before initiation of recruitment, a meta-
analysis19 of chlorhexidine studies reported a 17% 
mortality reduction. The technical advisory group 
therefore recommended a revised sample size of 
42 570 newborn babies (473 women per cluster) to detect 
a similar all-cause neonatal mortality rate reduction. We 
used an intention-to-treat (ITT) analysis for both primary 
and secondary outcomes. In response to reviewer 
requests, we also did a post-hoc pooled analysis of our 
primary outcomes together with those of the similar trial 
done in Pemba Island, Tanzania.12 Risk estimates from 
both Pemba Island and Zambia were combined using 
metan command in Stata. Primary data from both 
studies were pooled and analysed with Poisson regression 
model, adjusting for clustering. 
We examined the effect on neonatal mortality of the 
timing of first chlorhexidine wash (<24 h or ≥24 h after 
birth) compared with dry cord care. In the per-protocol 
population, we used propensity-scores analysis to 
compare those who applied chlorhexidine in the first 
24 h of life to a matched subset of those in the dry cord 
care group. Characteristics matched included presence 
of danger signs in the child, maternal age, maternal 
education, and delivery location. We calculated risk ratios 
(RR; 95% CIs) using generalised estimating equations 
(GEE) models, using an exchangeable correlation matrix, 
Chlorhexidine (n=18 510) Dry cord care (n=19 346)
Antenatal visits attended 3·3 (0·0) 3·4 (0·0)
Male infant 9055/18 155 (49·9%) 9396/19 081 (49·2%)
Low birthweight (<2500 g) 849/11 337 (7·5%) 836/12 085 (6·9%)
Mean birthweight (g [SD]) 3101·8 (495·8) 3117·5 (503·1)
Premature (<37 weeks; based on last 
menstrual period)
3484/16 763 (20·8%) 3521/17 286 (20·4%)
HIV-exposed neonate (n=17 878) (n=18 877) 
Reactive 1612 (9·0%) 1461 (7·7%)
Non-reactive 15 999 (89·5%) 17 273 (91·5%)
Unavailable 267 (1·5%) 143 (0·8%)
Place of delivery (n=18 155) (n=19 014) 
Hospital 2068 (11·4%) 3057 (16·1%)
Health-care centre 9388 (51·7%) 9147 (48·1%)
Home 6509 (35·9%) 6682 (35·1%)
Other 190 (1·0%) 128 (0·7%)
Delivery attendant (n=17 822) (n=18 626) 
Nurse or midwife 10 182 (57·1%) 10 260 (55·1%)
Trained traditional birth attendant 2174 (12·2%) 2556 (13·7%)
Untrained traditional birth attendant 692 (3·9%) 446 (2·4%)
Family member or relative 4030 (22·6%) 4400 (23·6%)
Mother delivered alone 487 (2·7%) 567 (3·0%)
Other 257 (1·4%) 397 (2·1%)
Used razor blade provided in CDK 15 453/18 008 (85·8%) 16 928/18 884 (89·6%)
Used gloves provided in CDK 17 558/18 008 (97·5%) 18 217/18 884 (96·5%)
Delivery mode (n=17 831) (n=18 750)
Vaginal 17 549 (98·4%) 18 387 (98·1%)
Vaginal with forceps 61 (0·3%) 123 (0·7%)
Vaginal with vacuum 20 (0·1%) 13 (0·1%)
Caesarean section 201 (1·1%) 227 (1·2%)
Drying of infant (n=17 542) (n=18 366) 
Before the placenta was delivered 13 055 (74·4%) 12 804 (69·7%)
After the placenta was delivered 3874 (22·1%) 4707 (25·6%)
Baby not dried before being wrapped 102 (0·6%) 233 (1·3%)
Do not know 511 (2·9%) 622 (3·4%)
Breastfeeding initiated in ≤1 h after delivery 15 825/17 729 (89·3%) 16 761/18 781 (89·2%)
Data are mean (SD), n (%), or n/N (%). CDK=clean delivery kit. 
Table 2: Characteristics of infants born alive in Southern Province, Zambia
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accounting for clustering by health facility for all analyses 
(ITT and per protocol).
Baseline characteristics potentially associated with the 
outcomes were compared between the two groups using 
appropriate tests. Variables were compared between 
groups using the χ² test, Fisher’s exact test, t-tests, or 
non-parametric Wilcoxon rank sum tests, as appropriate 
for continuous or categorical variables. We investigated 
the effects of adjusting for baseline characteristics. Key 
covariates considered for inclusion were sex, low 
birthweight (<2500 g), prematurity (gestational age 
<37 weeks based on last menstrual period), maternal age, 
maternal education, parity, birth location, distance from 
health facility, frequency of application of non-study 
substances to the umbilical cord, and exclusive 
breastfeeding. All statistical analyses were completed 
using SAS (version 9.3). This study is registered at 
ClinicalTrials.gov, number NCT01241318.
Role of the funding source
The funder provided input on study design, but had no 
role in data collection, data analysis, data interpretation, 
or writing of the report. KEAS and the corresponding 
author (DHH) had full access to all the data in the study 
and had final responsibility for the decision to submit for 
publication.
Results 
From Feb 15, 2011, to Jan 30, 2013, we screened 
42 536 pregnant women from 90 eligible clusters 
(12 urban, 56 rural ≤40 km from road, and 22 rural sites 
>40 km from road).14 41 110 (97·0%) women were eligible, 
of whom 39 679 (96·5%) were enrolled (figure 1). The 
mean enrolment per cluster was 436·2 women (SD 65·3) 
in the chlorhexidine group (45 clusters) and 445·5 women 
(59·5) in the dry cord care group (45 clusters). Before 
delivery, 1542 (3·8%) women were lost to follow-up, 
withdrew, had false pregnancies, or had spontaneous 
or elective abortions; six women died. 38 131 women 
delivered 38 579 children (443 sets of twins and five sets 
of triplets)—723 stillbirths and 37 856 livebirths. 
37 690 (99·6%) newborn babies survived the first 24 h. Of 
all livebirths, 18 450 (99·7%) newborn babies in the 
chlorhexidine group and 19 308 (99·8%) newborn babies 
in the dry cord care group were followed up to day 28 
post-partum or death.
Maternal sociodemographic and health characteristics, 
as well as labour and delivery practices, were similar 
between treatment groups (tables 1 and 2). Of all 
livebirths, 87·8% used the surgical blade from the clean 
delivery kit for cord cutting; 35·4% delivered at home, 
and 63·8% delivered in a health facility.
In the intervention group, 16 660 (90·0%) babies had 
chlorhexidine applied on the day of delivery and 
18 114 (97·9%) babies had at least one chlorhexidine 
application (table 3). A slightly higher number of babies 
in the dry cord care group had non-chlorhexidine 
applications than in the intervention group (table 3).
Overall, the neonatal mortality rate at 28 days post-
partum was lower than expected (14·4 deaths per 
1000 livebirths); 30% of all 545 neonatal deaths occurred 
on the day of birth (day 0; figure 2). The all-cause neonatal 
mortality rate was not significantly different between 
groups (15·2 deaths per 1000 livebirths in the 
chlorhexidine group vs 13·6 deaths per 1000 livebirths in 
the dry cord care group; RR 1·12, 95% CI 0·88–1·44; 
table 4). With the ITT analysis limited to newborn babies 
who survived the first 24 h, the neonatal mortality rate in 
the chlorhexidine group was slightly higher than in the 
Chlorhexidine 
(n=18 510)
Dry cord care 
(n=19 346)
Applied chlorhexidine until 
3 days after cord dropped off
15 949 (92·0%)* ¨
First application ≤24 h of birth 16 660 (90·0%) ¨
First application ≤48 h of birth 17 815 (96·2%) ¨
No chlorhexidine application 396 (2·1%) ¨
One application of 
chlorhexidine
69 (0·4%) ¨
Two or more applications of 
chlorhexidine
18 045 (97·5%) ¨
Days of chlorhexidine 
application
9·3 (2·5) ¨
Non-study cord application 
made
1699 (9·2%) 2450 (12·7%)
Participant follow-up   
day 1 17 921 (96·8%) 18 937 (97·9%)
day 4† 17 876 (97·7%) 18 816 (98·2%)
day 10‡ 17 957 (98·4%) 18 918 (98·9%)
day 28§ 18 096 (99·6%) 18 968 (99·6%)
Data are n (%), or mean (SD). *Of 17 332 infants. †Denominator is 18 301 infants 
in the chlorhexidine group and 19 165 in the dry cord care group. ‡Denominator 
is 18 244 infants in the chlorhexidine group and 19 127 in the dry cord care group. 
§Denominator is 18 168 infants in the chlorhexidine group and 19 045 in the dry 
cord care group. 
Table 3: Chlorhexidine compliance, umbilical cord applications, and study 
follow-up (n=37 856 livebirths)
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Figure 2: Neonatal mortality by day of age at death, by study group
545 deaths during 28 days post-partum.
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dry cord care group (RR 1·12, 95% CI 0·86–1·47). In 
the as practiced analysis by use of a propensity score 
approach, with intervention group limited to newborn 
babies who survived the first 24 h, the neonatal mortality 
rate was 8·5 deaths per 1000 livebirths for those with 
chlorhexidine applied on the day of delivery and was 
9·3 deaths per 1000 livebirths in the dry cord care group 
(RR 0·94, 95% CI 0·72–1·22).
Chlorhexidine application was not associated with 
decreased neonatal mortality in any of the pre-specified 
stratified analyses (table 5). Specifically no differences 
were noted in neonatal mortality rate for babies who were 
born premature or of low birthweight, whose mothers 
had known HIV status, or who were born in health-care 
facilities versus at home (table 5).
Omphalitis was diagnosed in 200 (0·5%) newborn 
babies, of whom 82 (41%; 4·43 cases per 1000 livebirths) 
were in the chlorhexidine group and 118 (59%; 6·10 cases 
per 1000 livebirths) were in the dry cord care group 
(RR 0·73, 95% CI 0·47–1·13). The finding did not differ 
substantially when restricted to babies with chlorhexidine 
applied in the first 24 h (0·76, 0·48–1·18; table 6). 
Nine adverse events associated with chlorhexidine 
were reported; one case was of ocular exposure (grade 2 
and did not require hospital admission) and 
eight episodes were of local skin irritation (grade 1). No 
cases of accidental ingestion, contact dermatitis, or 
anaphylaxis were reported. 
Discussion
Chlorhexidine did not reduce neonatal mortality 
compared with dry cord care in the Southern Province of 
Zambia. Chlorhexidine was not more effective in either 
the ITT analysis or the as practised analyses in reducing 
neonatal mortality. Stratified analyses examining delivery 
location, birthweight, prematurity, and maternal HIV 
status also did not show significant reductions in 
neonatal mortality rate. With the need for simple 
interventions to prevent neonatal mortality in low-
income and middle-income settings, chlorhexidine has 
appeared promising based on data in south Asia. 
However, in the context of relatively high rates of facility 
delivery (63%) and lower neonatal mortality rate 
(14·4 deaths per 1000 livebirths), chlorhexidine did not 
reduce neonatal mortality in Zambia.
In this large, cluster-randomised controlled trial with 
more than 37 800 liveborn children, less than 4% of 
enrolled women were lost before delivery, and less than 
1% were lost to follow-up during the neonatal period. 
Compliance in the chlorhexidine and dry cord care groups 
was excellent, with low levels of non-study substances 
applied to the umbilical stump. The study was designed 
as an effectiveness trial, a real-world scenario in which 
the mother, attendant, or family member would apply the 
chlorhexidine rather than study personnel.
The study has several limitations. First, the observed 
neonatal mortality rate in the dry cord care group was 
50% lower than the expected neonatal mortality rate 
(37 deaths per 1000 livebirths).13 This low figure might be 
partly due to the package of services that all women in 
the study received—clean delivery kit, referral to clinic 
in the presence of maternal or neonatal danger signs, 
newborn health messages, in addition to antenatal clinic 
visits, and home visits in the early neonatal period. One 
aspect of this messaging, which was equally applied in 
the dry cord care and chlorhexidine groups, was an 
emphasis on keeping the cord clean and dry. The 
repeated cord care messages were done in an attempt to 
have the dry cord care group closely adhere to WHO 
guidelines. However, these similarities between groups 
might have resulted in better cord care practices in the 
context of the trial and thereby resulted in lower neonatal 
mortality rates in both groups. Additionally, the baseline 
neonatal mortality rate data were based on the 2007 
Zambia DHS.13 By contrast, the 2013–14 Zambia DHS 
revealed a neonatal mortality rate of 24 deaths per 
1000 livebirths, so neonatal mortality has been 
progressively decreasing in Zambia during this period. 
Notably, the neonatal mortality rate had decreased from 
37 deaths to 23 deaths per 1000 livebirths in Southern 
Livebirths Neonatal 
deaths
NMR per 
1000 
livebirths
Relative risk 
(95% CI)* 
Intention-to-treat analysis (primary outcomes)
All-cause neonatal mortality (including day 0 deaths) 
All livebirths 37 856 545 14·4
Chlorhexidine 18 510 
(48·9%)
282 
(51·7%)
15·2 1·12 
(0·88–1·44)
Dry cord care 19 346 
(51·1%)
263 
(48·3%)
13·6
All-cause neonatal mortality (excluding day 0 deaths)
All livebirths who 
survived day 0
37 690 386 10·2
Chlorhexidine 18 424 
(48·9%)
200 
(51·8%)
10·9 1·12 
(0·86–1·47)
Dry cord care 19 266 
(51·1%)
186 
(48·2%)
9·7
As practiced analysis
All-cause neonatal mortality (excluding day 0 deaths) 
All livebirths 35 871 327 9·11 ··
Chlorhexidine† 16 645 141 
(0·8%)
8·5 0·88 
(0·66–1·16)
Dry cord care 19 266 186 
(1·0%)
9·7
Propensity-score analysis (excluding day 0 deaths)‡ 
Chlorhexidine† 16 400 
(50%)
132 
(0·8%)
8·0 0·94 
(0·72–1·22)
Dry cord care 16 400 
(50%)
141 
(0·9%)
8·6
NMR=neonatal mortality rate. *Generalised estimating equations were used to 
adjust point estimate and CIs for cluster-randomised design. †Chlorhexidine 
applied ≤24 h after birth. ‡Denominator is 32 800 births.
Table 4: Neonatal mortality by study group 
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Province. Thus, secular trends existed, resulting in lower 
neonatal mortality rates than expected during the study 
period in addition to trial-specific interventions that 
might have further lowered all-cause neonatal mortality 
rates, and which resulted in the study being 
underpowered. However, a pooled analysis of our 
Zambian and the completed Pemba Island12 data, with 
roughly double the sample size, showed no suggestion of 
a benefit of chlorhexidine on neonatal mortality 
(RRpooled 1·02, 95% CI 0·86–1·20, and RRmeta 0·99, 95% CI 
0·80–1·23).
Only 89% (37 856 of 42 570) of the target sample size 
was attained. When we completed a post-hoc power 
calculation (as previously described) with the obtained 
sample size and observed neonatal mortality rate, we had 
80% power to detect a 28% reduction in neonatal 
mortality rate, which is greater than the reduction 
observed in the south Asian data meta-analysis, but more 
in line with observations in Nepal20 and Pakistan.6,19 The 
observed incidence of omphalitis was lower than 
expected; it is possible that mild or moderate cases were 
under-reported as diagnosis was based on purulent 
discharge or redness at the umbilical stump.
To date, the evidence base for a global chlorhexidine 
policy recommendation has been limited to three cluster-
randomised community-based studies5–7,19 in south Asia 
comparing chlorhexidine cord washes to dry cord care. A 
cluster-randomised trial in Nepal5 reported a trend 
towards lower neonatal mortality among all neonates 
receiving daily chlorhexidine, lower mortality among 
neonates receiving chlorhexidine in the first 24 h after 
birth, and significantly less omphalitis than in neonates 
receiving dry cord care. A study7 with three groups 
undertaken in rural Bangladesh showed a significant 
reduction in neonatal mortality in the group who received 
a single umbilical cord cleansing on day 1 post partum, 
but counterintuitively did not show a similar effect in 
neonates who had daily umbilical cord washes for 
7 days post-partum.7 Finally, in rural Pakistan,6 daily 
chlorhexidine cord applications resulted in significant 
reductions in neonatal mortality and omphalitis.6 All 
three studies5–7 comparing chlorhexidine with dry cord 
care were completed in densely-populated rural areas of 
south Asia with high neonatal mortality rates (≥30 deaths 
per 1000 livebirths) and predominantly home deliveries.
The reported effect of chlorhexidine on neonatal 
mortality observed in Nepal, Bangladesh, and Pakistan 
from 2002 to 2009 might not be generalisable to many 
sub-Saharan African countries where antenatal care 
services are used more frequently, there are more facility-
based deliveries, and, in some settings, a lower neonatal 
mortality rate.21 Global efforts to encourage facility-based 
deliveries to reduce maternal mortality might be blunting 
the benefits of chlorhexidine for neonates. Additionally, 
overall secular trends towards lower neonatal mortality 
globally might contribute towards the non-effect of chlor-
hexidine.21–23 Important differences exist between the 
Livebirths Neonatal 
deaths
NMR per 
1000 
livebirths
Relative risk* 
(95% CI)
Birthweight (n=23 422)
Low birthweight (<2500 g)
Chlorhexidine 849 (3·6%) 21 (0·1%) 24·7 0·73 (0·39–1·37)
Dry cord care 836 (3·6%) 28 (0·1%) 33·4 ¨
Normal birthweight (≥2500 g)
Chlorhexidine 10 488 (44·8%) 57 (0·2%) 5·4 1·33 (0·87–2·05)
Dry cord care 11 249 (48·0%) 46 (0·2%) 4·1 ¨
Prematurity (n=34 039) 
Premature (<37 weeks)
Chlorhexidine 3484 (10·2%) 111 (0·3%) 31·9 1·03 (0·74–1·44)
Dry cord care 3521 (10·3%) 109 (0·3%) 31·0 ¨
Normal gestational age 
(≥37 weeks)
Chlorhexidine 13 269 (30·9%) 135 (0·4%) 10·2 1·16 (0·86–1·59)
Dry cord care 13 765 (40·4%) 120 (0·4%) 8·7 ¨
Maternal HIV status known (n=36 593) 
Infant exposed to HIV (n=3103)
Chlorhexidine 1631 (52·6%) 38 (1·2%) 23·2 1·14 (0·62–2·11)
Dry cord care 1472 (47·4%) 30 (1·0%) 20·4 ¨
Infant not exposed to HIV (n=33 490)
Chlorhexidine 15 999 (47·8%) 220 (0·7%) 13·7 1·13 (0·87–1·44)
Dry cord care 17 273 (51·6%) 211 (0·6%) 12·2 ¨
Delivery location (n=37 165)
Health facility or hospital (n=23 658)
Chlorhexidine 11 455 (48·4%) 177 (0·7%) 15·5 1·09 (0·82–1·46)
Dry cord care 12 203 (51·6%) 172 (0·7%) 14·1 ¨
Home delivery (n=13 507)
Chlorhexidine 6698 (49·6%) 95 (0·7%) 14·2 1·25 (0·86–1·83)
Dry cord care 6809 (50·4%) 77 (0·6%) 11·3 ¨
Data are n (%), unless otherwise specified. NMR=neonatal mortality rate. *Generalised estimating equations were used 
to adjust point estimate and CIs for cluster-randomised design. 
Table 5: Neonatal mortality by pre-specified health indicators
Livebirths Cases Risk per 
1000 
livebirths
Relative 
risk* 
(95% CI)
Intention-to-treat analysis
All livebirths 37 856 200 5·28 ¨
Chlorhexidine 18 510 
(49·0%)
82 
(41·0%)
4·43 0·73 
(0·47–1·13)
Dry cord care 19 346 
(51·2%)
118 
(59·0%)
6·10 ¨
As practiced analysis 
Chlorhexidine† 16 660 
(46·3%)
77 
(39·5%)
4·62 0·76 
(0·48–1·18)
Dry cord care 19 346 
(53·7%)
118 
(60·5%)
6·10 ¨
*Generalised estimating equations were used to adjusted point estimate and CIs 
for cluster-randomised design. †First application <24 h after birth. 
Table 6: Omphalitis incidence in newborn babies
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south Asian and Zambian populations regarding cord 
care, newborn health, and other newborn-care practices. 
In our Zambian study, 63% of women enrolled delivered 
at a facility, compared with less than 20% of deliveries for 
the three south Asian studies.5–7 By contrast with the 
predominantly rural locations in south Asia, the study 
site in Southern Province included a mixture of rural and 
urban sites. In Zambia, only 7% of chlorhexidine and 
11% of dry cord care groups had applied non-study 
substances (eg, breastmilk, baby powder, charcoal, dust) 
to the cord. In the south Asia studies,6,7,20 50–90% of the 
children in Nepal and Pakistan had additional non-study 
substances placed on the cord, including mustard oil and 
coal. In our qualitative research completed before trial 
initiation, mothers, grandmothers, and health workers 
described alternative cord application substances and 
cultural neonatal care practices.8 However, the newborn 
baby care messaging that was provided to all ZamCAT 
study participants could have reduced such alternative 
cord applications and increased the number of infants 
who received actual dry cord care. Additionally, only 7% 
of ZamCAT infants were of low birthweight compared 
with nearly a third of those in the Nepal5 and Bangladesh7 
studies.
In view of the different contexts (community vs facility 
delivery, low neonatal mortality rate vs high neonatal 
mortality rate, and cultural practices of cord care) of the 
south Asian trials compared with those undertaken in 
sub-Saharan Africa, a rigorous meta-analysis of all the 
major trials of chlorhexidine cord care is needed, with 
careful attention paid to weighting of the studies in the 
meta-analysis, quality scoring, and other related statistical 
details. Ideally, this meta-analysis should be done under 
the coordination of an independent objective party. The 
results of this analysis will be of crucial importance to the 
development of revised WHO guidelines for umbilical 
cord care in resource-limited countries.
WHO’s guidelines10 recommend use of chlorhexidine 
if an infant is delivered at home in environments with 
a high neonatal mortality rate (≥30 deaths per 
1000 livebirths). Rolling out chlorhexidine to all low-
income and middle-income settings risks the misuse of 
resources—time, money, political capital, and, most 
importantly, patient trust. Simple, evidence-based 
solutions exist to reduce neonatal mortality in resource-
limited settings—skilled birth attendants, neonatal 
resuscitation, access to basic and comprehensive 
emergency obstetric care, postnatal visits, kangaroo 
mother care, early detection and appropriate 
management of neonatal sepsis, provision of clean 
delivery kits, clean dry cord care, and exclusive 
breastfeeding can substantially reduce neonatal 
mortality.4,24 Although chlorhexidine is potentially 
beneficial in places with a high neonatal mortality rate 
and home-based delivery environments in south Asia, 
the treatment had no effect on neonatal mortality 
in Zambia, an environment with a lower neonatal 
mortality rate, more facility-based deliveries, and with 
representation of both urban and rural sites. On the basis 
of these findings, we believe chlorhexidine should not be 
globally implemented, especially in moderate neonatal 
mortality environments in Africa.
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